Sanofi to acquire Principia Biopharma for $3.7B August 17, 2020 Auto Bot BioPharma, biopharma nl, California, France, multiple sclerosis, Paris, Sanofi, South San Francisco 0 The French drugmaker will take full control of SAR442168, a BTK inhibitor developed for multiple sclerosis that it in-licensed from the California biotech company in 2017.